vs

Side-by-side financial comparison of Pulmonx Corp (LUNG) and Pathfinder Bancorp, Inc. (PBHC). Click either name above to swap in a different company.

Pulmonx Corp is the larger business by last-quarter revenue ($20.6M vs $11.8M, roughly 1.7× Pathfinder Bancorp, Inc.). Pathfinder Bancorp, Inc. runs the higher net margin — -52.9% vs -66.3%, a 13.4% gap on every dollar of revenue. On growth, Pulmonx Corp posted the faster year-over-year revenue change (-8.7% vs -22.6%). Over the past eight quarters, Pathfinder Bancorp, Inc.'s revenue compounded faster (3.0% CAGR vs -0.5%).

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

Pathfinder Bancorp, Inc. is a regional bank holding company headquartered in New York, U.S. It operates Pathfinder Bank serving the central New York market, offering retail and commercial banking services including deposit accounts, mortgages, business loans and wealth management for individual consumers and small to medium-sized enterprises.

LUNG vs PBHC — Head-to-Head

Bigger by revenue
LUNG
LUNG
1.7× larger
LUNG
$20.6M
$11.8M
PBHC
Growing faster (revenue YoY)
LUNG
LUNG
+14.0% gap
LUNG
-8.7%
-22.6%
PBHC
Higher net margin
PBHC
PBHC
13.4% more per $
PBHC
-52.9%
-66.3%
LUNG
Faster 2-yr revenue CAGR
PBHC
PBHC
Annualised
PBHC
3.0%
-0.5%
LUNG

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
LUNG
LUNG
PBHC
PBHC
Revenue
$20.6M
$11.8M
Net Profit
$-13.7M
$-5.6M
Gross Margin
77.9%
Operating Margin
-40.9%
-81.1%
Net Margin
-66.3%
-52.9%
Revenue YoY
-8.7%
-22.6%
Net Profit YoY
5.5%
-242.4%
EPS (diluted)
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LUNG
LUNG
PBHC
PBHC
Q1 26
$20.6M
Q4 25
$22.6M
$11.8M
Q3 25
$21.5M
$13.1M
Q2 25
$23.9M
$9.3M
Q1 25
$22.5M
$12.6M
Q4 24
$23.8M
$15.3M
Q3 24
$20.4M
$13.4M
Q2 24
$20.8M
$10.7M
Net Profit
LUNG
LUNG
PBHC
PBHC
Q1 26
$-13.7M
Q4 25
$-10.4M
$-5.6M
Q3 25
$-14.0M
$626.0K
Q2 25
$-15.2M
$31.0K
Q1 25
$-14.4M
$3.0M
Q4 24
$-13.2M
$3.9M
Q3 24
$-14.1M
$-4.6M
Q2 24
$-15.3M
$2.0M
Gross Margin
LUNG
LUNG
PBHC
PBHC
Q1 26
77.9%
Q4 25
77.6%
Q3 25
74.7%
Q2 25
72.1%
Q1 25
72.5%
Q4 24
74.0%
Q3 24
73.7%
Q2 24
73.7%
Operating Margin
LUNG
LUNG
PBHC
PBHC
Q1 26
-40.9%
Q4 25
-43.8%
-81.1%
Q3 25
-66.9%
5.1%
Q2 25
-62.0%
0.4%
Q1 25
-64.6%
29.5%
Q4 24
-56.5%
55.4%
Q3 24
-69.3%
-43.1%
Q2 24
-75.2%
23.3%
Net Margin
LUNG
LUNG
PBHC
PBHC
Q1 26
-66.3%
Q4 25
-46.1%
-52.9%
Q3 25
-64.9%
4.8%
Q2 25
-63.6%
0.3%
Q1 25
-64.1%
23.6%
Q4 24
-55.4%
37.7%
Q3 24
-69.4%
-34.6%
Q2 24
-73.7%
18.7%
EPS (diluted)
LUNG
LUNG
PBHC
PBHC
Q1 26
$-0.33
Q4 25
$-0.25
Q3 25
$-0.34
$0.47
Q2 25
$-0.38
$0.47
Q1 25
$-0.36
Q4 24
$-0.33
Q3 24
$-0.36
$0.41
Q2 24
$-0.39
$0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LUNG
LUNG
PBHC
PBHC
Cash + ST InvestmentsLiquidity on hand
$61.6M
Total DebtLower is stronger
$37.3M
$14.1M
Stockholders' EquityBook value
$45.8M
$122.5M
Total Assets
$120.0M
$1.4B
Debt / EquityLower = less leverage
0.82×
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LUNG
LUNG
PBHC
PBHC
Q1 26
$61.6M
Q4 25
$69.8M
Q3 25
$76.5M
Q2 25
$75.5M
Q1 25
$74.6M
Q4 24
$70.9M
Q3 24
$63.3M
Q2 24
$63.5M
Total Debt
LUNG
LUNG
PBHC
PBHC
Q1 26
$37.3M
Q4 25
$37.1M
$14.1M
Q3 25
$37.1M
$18.7M
Q2 25
$37.1M
$21.0M
Q1 25
$37.2M
$17.6M
Q4 24
$37.2M
$27.1M
Q3 24
$37.2M
$39.8M
Q2 24
$37.2M
$45.9M
Stockholders' Equity
LUNG
LUNG
PBHC
PBHC
Q1 26
$45.8M
Q4 25
$54.1M
$122.5M
Q3 25
$60.0M
$126.3M
Q2 25
$69.1M
$124.4M
Q1 25
$77.7M
$124.9M
Q4 24
$85.8M
$121.5M
Q3 24
$93.9M
$120.2M
Q2 24
$101.2M
$123.3M
Total Assets
LUNG
LUNG
PBHC
PBHC
Q1 26
$120.0M
Q4 25
$129.3M
$1.4B
Q3 25
$138.3M
$1.5B
Q2 25
$147.2M
$1.5B
Q1 25
$150.7M
$1.5B
Q4 24
$162.8M
$1.5B
Q3 24
$167.4M
$1.5B
Q2 24
$172.6M
$1.4B
Debt / Equity
LUNG
LUNG
PBHC
PBHC
Q1 26
0.82×
Q4 25
0.69×
0.11×
Q3 25
0.62×
0.15×
Q2 25
0.54×
0.17×
Q1 25
0.48×
0.14×
Q4 24
0.43×
0.22×
Q3 24
0.40×
0.33×
Q2 24
0.37×
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LUNG
LUNG
PBHC
PBHC
Operating Cash FlowLast quarter
$11.7M
Free Cash FlowOCF − Capex
$10.4M
FCF MarginFCF / Revenue
88.1%
Capex IntensityCapex / Revenue
10.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$18.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LUNG
LUNG
PBHC
PBHC
Q1 26
Q4 25
$-7.1M
$11.7M
Q3 25
$-8.2M
$7.0M
Q2 25
$-3.9M
$-3.7M
Q1 25
$-13.2M
$5.7M
Q4 24
$-6.7M
$11.2M
Q3 24
$-7.2M
$11.8M
Q2 24
$-5.8M
$1.5M
Free Cash Flow
LUNG
LUNG
PBHC
PBHC
Q1 26
Q4 25
$-7.1M
$10.4M
Q3 25
$-8.3M
$6.9M
Q2 25
$-4.0M
$-4.0M
Q1 25
$-13.5M
$5.1M
Q4 24
$-6.8M
$9.1M
Q3 24
$-7.7M
$11.3M
Q2 24
$-6.2M
$637.0K
FCF Margin
LUNG
LUNG
PBHC
PBHC
Q1 26
Q4 25
-31.4%
88.1%
Q3 25
-38.4%
52.8%
Q2 25
-16.6%
-42.6%
Q1 25
-60.0%
40.1%
Q4 24
-28.8%
59.9%
Q3 24
-37.6%
84.3%
Q2 24
-30.0%
6.0%
Capex Intensity
LUNG
LUNG
PBHC
PBHC
Q1 26
Q4 25
0.1%
10.7%
Q3 25
0.4%
1.0%
Q2 25
0.2%
2.4%
Q1 25
1.3%
5.1%
Q4 24
0.5%
13.5%
Q3 24
2.0%
3.8%
Q2 24
2.3%
8.2%
Cash Conversion
LUNG
LUNG
PBHC
PBHC
Q1 26
Q4 25
Q3 25
11.26×
Q2 25
-120.55×
Q1 25
1.92×
Q4 24
2.87×
Q3 24
Q2 24
0.76×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LUNG
LUNG

Segment breakdown not available.

PBHC
PBHC

Other$5.6M47%
Banking$3.7M31%
Deposit Account$1.5M13%
Financial Service Other$1.0M9%

Related Comparisons